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Abstract 
Introduction: Tuberculous meningitis (TM) causes substantial morbidity and mortality in 
humans. Human TM has been known to be induced by bacteria from the Mycobacterium 
tuberculosis complex (MTBC), such as M. tuberculosis and M. bovis.  
Case Presentation: We describe a case of meningitis treated with fosfomycin, which showed 
partial effectiveness in an 80-year-old patient. After a lethal myocardial infarction, M. caprae 
(MC) was identified in cerebrospinal fluid culture. This isolated acid-fast organism was first 
identified as MTBC by MTBC-specific PCR (16S rDNA-PCR). Furthermore, species-specific 
identification of the isolate was done by gyrB PCR-restriction fragment length polymorphism 
analysis of a part of gyrB DNA. Colony morphology of the isolated MC strain showed 
dysgonic growth on Lowenstein-Jensen medium. The strain was susceptible to pyrazinamide 
(PZA).  
Conclusion: This isolated strain was convincingly identified as MC according to the 
phenotypic and genotypic characteristics and PZA sensitivity. This is the first report of MC 
causing TM. 
 
Introduction 
In tuberculous meningitis (TM), Mycobacterium tuberculosis and, more rarely, M. 
bovis (MB), formerly known as M. bovis ssp. bovis [1], have been reported as pathogens. 
Clinically, TM should be suspected in patients presenting a progressive, subacute illness 
with headache, meningism, cranial-nerve involvement and hydrocephalus development 
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potentially leading to stupor and coma. Diagnosis depends on cerebrospinal fluid (CSF) 
analysis typically revealing predominantly lymphocytic pleocytosis, high protein 
content, low glucose and high lactate. The definitive diagnosis of TM relies on CSF 
cultures that take at least 6 weeks [2] to develop, which is why tuberculostatic therapy 
is almost always started before the definitive diagnosis has been made. 
Here, we present a patient with TM which, in postmortem analysis, turned out to 
have been caused by M. caprae (MC), a member of the M. tuberculosis complex (MTBC) 
including M. tuberculosis, M. africanum, MB, M. canetti, M. microti, M. pinnipedia and M. 
pinnipedia sp. nov. 
Case Report 
An 80-year-old man, without an agricultural background and with a history of fully remitted 
prostate cancer, hypernephroma 15 years before and a coronary artery bypass graft 6 years 
previously, was admitted to a tertiary care hospital for a subacute gait disorder suspicious for non-
pressure hydrocephalus, and slight disorientation. Two non-contrast MRI brain scans were 
incomplete because of psychomotor unsteadiness. However, they revealed brain atrophy, an internal 
hydrocephalus and relevant cerebral microangiopathy (fig. 1). CSF revealed a lymphomonocytic 
pleocytosis [high leukocyte count of 1,089/mm3 (reference value 0–3), and elevated protein of 1,040 
mg/dl (reference value <50)]. Serology, microscopy and CSF culture did not reveal bacteria, thus 
excluding more rare pathogens like Listeria, Brucella, Leptospira, Rickettsia and Tropheryma, fungi 
such as cryptococci, and neurotropic viruses including HIV. Having diagnosed meningitis of unknown 
origin, standard first-line antibiotic treatment with ceftriaxone and ampicillin was introduced. As the 
patient failed to improve within 22 days, he was transferred to our hospital because of a progressive 
loss of consciousness together with meningeal signs. 
Brain CT did not reveal new information. CSF again showed a high cell count of 1,080/mm3, with 
31% neutrophils and 56% lymphocytes (fig. 2a), low glucose (48 mg/dl, with serum glucose 180 
mg/dl), high protein content (339 mg/dl), and high lactate [6.1 mmol/l (reference value 1.2–2.1)]. CSF 
pressure was elevated to 25 cm H2O. Again, no bacteria were detected, and Ziehl-Neelsen’s stain was 
negative for Mycobacterium. Antibiotics were switched to meropenem plus ampicillin and, with TM 
included in the differential diagnosis, to a combination of rifampicin (450 mg i.v./day), isoniazid (300 
mg p.o./day), pyrazinamide (3 g p.o. 2 times/week) and ciprofloxacin (500 mg p.o./day). PCR detected 
no DNA of MC. During the days thereafter, triple analysis of bronchial secretions, urine and gastric 
lavage were all negative for Mycobacterium. Chest X-ray and abdominal sonography were also 
unremarkable. 
For the next 3 days, CSF pressure dropped to 19 cm H2O as a result of daily spinal taps. The 
patient’s condition improved. On the fifth day, he developed Lyell’s syndrome with a generalized rash 
and bullous exanthema leading to allergic shock which had to be treated with catecholamines (time 
course of C-reactive protein (CRP) and leukocyte cell count data in serum, fig. 2b). As 
antituberculotics may often cause such an event, and TM was not definitive, these drugs were 
stopped, and fosfomycin was initiated as a broad-spectrum antibiotic therapy for bacterial meningitis 
(3 × 3 g i.v./day). Additionally, glucosteroids and antihistamines were given for a total of 10 days. 
Within 2 weeks of treatment accompanied by several lumbar punctures to reduce CSF pressure, 
which indeed did not exceed 20 cm H2O, the patient recovered to cooperativeness. He refused a 
leptomeningeal biopsy to look for tuberculous granulomas. Within 14 days, the CSF leukocyte cell 
count dropped to 68/mm3 as revealed by a lymphocytic cell picture, and the protein content fell to 
55.9 mg/dl; CRP and serum white cell count decreased to reference values (fig. 2b). 
After 29 days, the patient was transferred to a rehabilitation center, where fosfomycin was 
discontinued. Over the next 2 weeks, his condition deteriorated, presenting progressive immobility, 
headache and somnolence. Due to his recently completed advance directive, neither a spinal tap nor 
antibiotic therapy was provided. Unfortunately, the patient died suddenly from an acute myocardial 
infarction. Autopsy was refused. 
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Two weeks after death, CSF cultures for mycobacteria demonstrated growth in the broth-based 
MGIT 960 system (Becton Dickinson Microbiology System, Heidelberg, Germany). The isolated acid-
fast organism was identified as MTBC by MTBC-specific PCR (16S rDNA-PCR). Species-specific 
identification of the isolate was performed by gyrB PCR-restriction fragment length polymorphism 
(RFLP) analysis of a part of gyrB DNA [3, 4]. This method consists of gyrB DNA amplification of the 
isolated MTBC, subsequent to the electrophoretic separation of the amplified products and finally of 
the 16S rDNA sequencing of a specific DNA 1,020-bp fragment. Differences in the gyrB sequences 
allow accurate discrimination of the MTBC and the species-specific identification of M. tuberculosis, M. 
microti, M. africanum I, MB and last, but not least, MC. Colony morphology of the isolated MC strain 
showed dysgonic growth on Lowenstein-Jensen (LJ) medium. The strain was susceptible to 
pyrazinamide (PZA) (100 µg/ml). 
Discussion 
Clearly, our patient was suffering from meningitis due to uncommon bacteria not 
identified by a broad battery of tests, and first-line antibiotics did not influence the 
course at all. We thus suspected TM on clinical grounds, based on the ineffectiveness of 
ceftriaxone plus ampicillin, hydrocephalus, a subchronic course, and compatible 
laboratory and CSF findings [5]. Antituberculotics unfortunately had to be stopped after 
3 days because of life-threatening Lyell’s syndrome. Because TM had not yet been 
settled, fosfomycin was introduced as a broad-spectrum alternative for bacterial 
meningitis, and the patient gradually improved clinically within a 3-week period, as did 
CSF and inflammation parameters. After the cessation of fosfomycin, the patient 
deteriorated again, supporting at least a partial effectiveness of fosfomycin. 
Unfortunately, the patient died from an unrelated cause. 
Surprisingly, postmortem MC, a member of the MTBC, was detected in CSF cultures, 
which highlights that time-consuming culture is more sensitive than Ziehl-Neelsen 
staining and PCR for MTBC. However, MC has never been reported to cause human TM. 
MC has been shown to induce pulmonary and extrapulmonary manifestations of human 
tuberculosis [6], lupus vulgaris [7] and pericarditis [8] (table 1). The close relationship 
between MC and particularly MB makes their species-specific identification difficult. In 
general, routine differentiation of MTBC is based on a number of phenotype 
characteristics and biochemical tests. MC and MB show ‘dysgonic growth’ on LJ 
medium, which means they have difficulty growing and are negative for nitrate 
reduction and niacin accumulation. The only criterion for their discrimination is MB’s 
intrinsic resistance to PZA and MC’s susceptibility to PZA. However, as PZA-susceptible 
subspecies of MB have very recently been reported [9], both species can be reliably 
identified using molecular biology techniques only. Of these techniques, the PCR-RFLP 
method used here proved useful for accurately differentiating MB from MC. This 
method is based on the amplification of a 1,020-bp fragment of the gyrB DNA from 
clinical isolates and on the detection of single nucleotide polymorphisms in the 
amplified gyrB sequences. Due to single nucleotide changes in their gyrB sequences, 
members of MTBC may be identified species specifically. In contrast to M. tuberculosis, 
MC and MB contain a specific adenine residue instead of a guanine residue in position 
756 of the 1,020-bp DNA fragment. With respect to MB, MC contains a guanine residue 
instead of a thymidine residue in position 1311, and a cytosine residue rather than a 
thymidine residue in position 1410 on the gyrB gene. The phenotypic and genotypic 
characteristics together with PZA sensitivity suggest that the isolated strain was 
reliably identified as MC. 
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MC has been isolated mainly in Europe (e.g. Spain, Austria, the Czech Republic, and 
in the Balkans) from cattle, goat, horse, cat, dog, pig, ferret, red deer and wild boar [10–
12]. Identification of isolates from human patients has revealed MC to be a human 
pathogen [6, 10, 11] that is probably transmitted to humans via contact with livestock 
[13]. A recent study from Spain detected MC in 0.3% of human tuberculosis [6], and MC 
caused a third of the human MB-associated tuberculosis cases reported between 1999 
and 2001 in Germany [10]. In particular, a high regional difference in MC’s prevalence 
became apparent: more than 80% of the cases were detected in southern Germany, 
whereas less than 10% occurred in the northern parts of Germany [10]. Interestingly, 
our patient came from southern Germany. 
Consumption of unpasteurized dairy products is often the source of infection, and 
that may also have been the case in our patient who had no close contact to animals. 
We can exclude accidental contamination, as MC has never been detected at the 
Institute of Microbiology before or since, and there have been no known cases of MC 
amongst our ICU personal. Altogether, though never reported before, there are 
plausible arguments supporting TM caused by MC. 
The effectiveness of fosfomycin in MC TM may be assumed. Our patient’s rapid initial 
clinical improvement was probably more likely due to lowering his elevated CSF 
pressure than to anti-inflammatory drug effects on meningitis; however, his further 
recovery, especially the improvement in CSF findings (fig. 2a, b), may be attributed to 
fosfomycin. A spontaneous improvement seems implausible, as TM is generally a 
progressive, fatal disease if treated inadequately. It also does not seem credible that a 
3-day course of standard antituberculotics including PZA was responsible. After 
stopping fosfomycin, the patient’s neurologic condition deteriorated again. This seems 
consistent, as standard antituberculous therapy in TM must be administered for several 
months. Thus, our patient’s course suggests that fosfomycin may be at least somewhat 
therapeutically effective. 
Conclusions 
Clinical and laboratory data suggested TM in our patient. Based on its phenotypic 
and genotypic characteristics, we reliably identified the isolated strain of the CSF 
culture as MC. MC can therefore cause TM in humans. Furthermore, the clinical course 
was positively influenced by fosfomycin. 
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Table 1. Clinical manifestations of human infections due to MC 
      
      
Disease Clinical manifestations Geographical range Age, years 
(n) 
Source of infection Reference 
      
      
Lupus 
vulgaris 
Right forehead, temple, cheek and 
earlobe  
Pulmonary tuberculosis 
Bavaria, Germany 68 
(1) 
Infected milk products 7 
            Lupus 
vulgaris 
Left side of the neck (20×30 mm), 
peripheral satellites 
Turkey 33 
(1) 
Direct contact with  
dairy cattle 
14 
            Tuberculosis Pulmonary Austria 39, 54, 66, 72 
(4) 
Farming area,  
stock animals 
13 
            Tuberculosis Pulmonary, cervical lymph node 
enlargement 
Croatia 7, 13 
(2) 
Cattle dairy farm 15 
            Tuberculosis Pulmonary, extrapulmonary 
(abdominal, cutaneous, urinary, bone, 
lymph node), unknown 
Germany 0–90 
(46) 
Unknown 10 
            Tuberculosis Pulmonary and extrapulmonary Spain, Morocco, Algeria,  
Israel, Nigeria, Kenya, Peru 
15–>65 
(21) 
Unknown 6 
            Tuberculosis Pericarditis Germany 76 
(1) 
Unknown 8 
      
      
 
 
 
 
 
Fig. 1. Non-contrast MRI of the patient’s brain shows slight atrophy, ventricular enlargement and 
cerebral microangiopathy. 
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Fig. 2.  Time course of leukocyte cell counts in CSF (a) and serum (b). The arbors illustrate the time 
interval of antibiotic therapy. Note the intermittent effect after fosfomycin therapy. 
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